Abstract
Breast cancer is the most prevalent malignancy in women globally, with metastatic disease accounting for approximately 90 % of breast cancer-related deaths. The development of breast cancer liver metastases in patients not only significantly reduces survival rates but also severely impairs quality of life. This review systematically examines therapeutic advances in the treatment of breast cancer liver metastases from 2010 to 2023, focusing on novel targeted agents (CDK4/6 inhibitors, PI3K/mTOR pathway inhibitors), immune checkpoint inhibitors, and local interventions. We provide evidence-based recommendations to optimize personalized treatment strategies and improve clinical outcomes for patients with breast cancer liver metastases.